Shopping Cart
- Remove All
- Your shopping cart is currently empty
Zotizalkib (TPX-0131) is an orally active and selective ALK inhibitor with antitumor activity for the study of non-small cell lung cancer.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,190 | In Stock | |
50 mg | $1,550 | In Stock | |
100 mg | $2,239 | In Stock |
Description | Zotizalkib (TPX-0131) is an orally active and selective ALK inhibitor with antitumor activity for the study of non-small cell lung cancer. |
Targets&IC50 | ALK (WT):1.4 nM |
In vitro | Zotizalkib effectively inhibited wild-type ALK with an IC50 value of 1.4 nM, and also showed inhibitory activity against 26 ALK resistance mutations. Zotizalkib also showed effective inhibition of ALK autophosphorylation in Ba/F3 cells expressing EML4-ALK G1202R, EML4-ALK G1202R/L1196M or EML4-ALK G1202R/L1198F mutations, with an IC50 value of about 3-10 nM. [1] |
In vivo | Zotizalkib was administered orally at a dose of 2-10 mg/kg twice daily for 2 weeks, with the 2 mg/kg, 5 mg/kg, and 10 mg/kg doses exhibiting 64%, 120%, and 200% dose-dependent tumor growth inhibition, respectively. [1] |
Alias | TPX-0131, TPX0131 |
Molecular Weight | 447.41 |
Formula | C21H20F3N5O3 |
Cas No. | 2648641-36-3 |
Smiles | C(F)(F)[C@H]1N2C=3C(=CN4C(N3)=C(C=N4)C(=O)NC(C)(C)COC=5C(C2)=CC(F)=CC5)OC1 |
Relative Density. | 1.56 g/cm3 (Predicted) |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
Solubility Information | DMSO: 20 mg/mL (44.7 mM), Sonication is recommended. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.